Abstract: . . .  population. BMJ 1995, vol. 311, p. 293-295. 4. Marentette M,Gerth W,Billings D,Zarnke K.Antihypertensive persistence and drug class. Can J Cardiol 2002, vol. 18, no 6, p. 649-656. 5. Caro J, Speckman J, Salas M, et coll. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999, vol. 160, p. 41-46. 6. Dickinson D, Raynor DKT. Ask the patients they may want to know more than you think. BMJ 2003, vol. 327, p. 861-862. 7. Deschamps M, Dyck A, Taylor J. What are we saying? Content and organization of patient counseling by community pharmacists. Canadian Pharmaceutical Journal 2003, vol. 236, no 6), p. 42-47. 8. Evans SW, John DN. A preliminary investigation of the interactions between UK and US community pharmacists and their prescription clients. Int J Pharm Pract 1995, vol. 3, p. 157-162. 9. Barnett C, Nykamp D, Ellington A. Patient-guided counseling in the community pharmacy setting. J Am Pharm Assoc 2000, vol. 40, p. 765-772. 10. McAlister FA, Laupacis A. Towards a better yardstick: the choice of treatment thresholds in hypertension . Can J Cardiol 1998, vol. 14, p.47-51. DITORIAL COLLABORATION SPCIALE  . . .
--2444,1,1222,1412,12220